IDEXX Laboratories Stock Price and Value Analysis

IDEXX Laboratories (NasdaqGS:IDXX) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold IDEXX Laboratories to reach your target.

Target type

IDXX Free Cash Flow Trend

Free Cash Flow trendline for IDXX
Free Cash Flow trendline for IDEXX Laboratories
CSV

Based on historical returns, we believe that IDEXX Laboratories can grow its free cash at a rate of about 27%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the IDXX Numbers

IDXX Price
(IDEXX Laboratories stock price per share)
$676.21
[?] IDXX Fair Price
(based on intrinsic value)
$228.37
[?] IDXX Safety Price (based on a variable margin of safety) $137.02
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 124% higher than other Healthcare stocks
[?] PE Ratio versus Industry 62% lower than other Diagnostics & Research stocks
[?] Cash Yield 0.38%
[?] Free Cash Flow Jitter 31%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,354,117 shares shorted. With 78,517,604 shares available for purchase and an average trading volume over the past 10 trading days of 472,120, it would take at least 5.0 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 874716 53.3
2009 874716 105
2010 874716 119
2011 874716 161
2012 874716 165
2013 874716 191
2014 874716 179
2015 874716 156
2016 874716 270
2017 874716 301
2018 874716 320
2019 874716 361
2020 874716 545
2021 874716 641
2022 874716 414
2023 874716 774
2024 874716 803
2025 874716 1,052

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 18 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $8,176 million against net income of $7,370 million, or 1.11 times.

In 2025, operating cash flow was 1.12 times net income, compared with 1.31 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $125 million, 10.5% of operating cash flow of $1,182 million, which leaves an estimated $1,057 million after capex. Across the 18 years with reported capex, it averaged 20.5% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 116 143 90 1.23
2009 122 175 50.7 1.43
2010 141 179 38.9 1.27
2011 162 218 49.7 1.35
2012 178 222 57.6 1.25
2013 188 246 77.6 1.31
2014 182 236 60.5 1.30
2015 192 222 82.9 1.15
2016 222 339 64.8 1.53
2017 263 373 74.4 1.42
2018 377 400 116 1.06
2019 428 459 155 1.07
2020 582 648 107 1.11
2021 745 756 120 1.01
2022 679 543 149 0.80
2023 845 907 134 1.07
2024 888 929 121 1.05
2025 1,059 1,182 125 1.12

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $5,481 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $5,133 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $1,217 million, 115.7% of estimated free cash flow of $1,052 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 270 n/a 304 304 112.5%
2017 301 n/a 283 283 93.8%
2018 320 n/a 369 369 115.3%
2019 361 n/a 302 302 83.7%
2020 545 n/a 183 183 33.6%
2021 641 n/a 747 747 116.5%
2022 414 n/a 820 820 198.1%
2023 774 n/a 71.9 71.9 9.3%
2024 803 n/a 837 837 104.2%
2025 1,052 n/a 1,217 1,217 115.7%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,024 million in 2008 and $4,304 million in 2025, a compound annual growth rate of 8.8% over 17 years.

Revenue rose 10.4% from 2024 to 2025.

Our estimated free cash flow was $1,052 million in 2025, 24.5% of revenue. In 2008 the estimated margin was 5.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 1,024 53.3 5.2%
2009 1,032 105 10.1%
2010 1,103 119 10.8%
2011 1,219 161 13.2%
2012 1,293 165 12.8%
2013 1,377 191 13.9%
2014 1,486 179 12.0%
2015 1,602 156 9.7%
2016 1,775 270 15.2%
2017 1,969 301 15.3%
2018 2,213 320 14.5%
2019 2,407 361 15.0%
2020 2,707 545 20.1%
2021 3,215 641 19.9%
2022 3,367 414 12.3%
2023 3,661 774 21.1%
2024 3,898 803 20.6%
2025 4,304 1,052 24.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $180 million against total liabilities of $1,745 million, or 10.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 52.1% of total assets in 2025, compared with 36.4% in 2009, an increase of 15.7 percentage points.

Stockholders equity was $1,605 million in 2025, compared with $515 million in 2009, a rise of 212.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 52.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 809 107 294 515
2010 897 157 323 574
2011 1,031 184 491 540
2012 1,104 224 467 636
2013 1,231 279 712 518
2014 1,384 323 1,267 118
2015 1,475 129 1,559 -84
2016 1,531 155 1,639 -108
2017 1,713 188 1,767 -53.8
2018 1,537 124 1,547 -9.2
2019 1,832 90.3 1,655 178
2020 2,295 384 1,662 633
2021 2,437 144 1,747 690
2022 2,747 113 2,138 609
2023 3,260 454 1,775 1,485
2024 3,293 288 1,698 1,595
2025 3,351 180 1,745 1,605

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $676.21, our model's value equals that price if free cash flow grows an average of 43.8 percent a year over the 10 projection years. Our model assumes 26.9 percent a year for this stock, so the price implies growth of 43.8 percent, which is above the 26.9 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 43.8 percent a year, free cash flow would grow about 37.7 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $204 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $540.97 40.3%
Current price $676.21 43.8%
20 percent above the current price $811.45 46.6%
Our model (stored fair price) $228.37 26.9%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

IDEXX Laboratories is priced at $676.21, above our fair value estimate of $228.37 and its safe value of $137.02.

Free cash flow was positive in all 18 fiscal years we have for IDEXX Laboratories under its current SEC filer.

IDEXX Laboratories's average free cash flow rose sharply, from $92.3 million in its earliest three years to $876 million in its latest three.

Year-to-year variability in free cash flow is uneven, measured at 31%.

Our value investing guide explains how to test these numbers against the filings themselves.

We do not have a dividend yield for IDEXX Laboratories.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 124% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 62% below the average for stocks in the Diagnostics & Research industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Diagnostics & Research industry, the ones closest in market capitalization to IDEXX Laboratories, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
IDEXX Laboratories (IDXX) 53,276 45.6 - 0.4% 196% above
IQVIA Holdings (IQV) 40,511 29.9 - - 523% above
Quest Diagnostics Incorporated (DGX) 28,416 25.7 1.3% 3.0% 25% above
Incyte Corporation (INCY) 23,364 58.5 - 0.6% 166% above
Medpace Holdings (MEDP) 17,078 33.9 - - 3621% above
Charles River Laboratories International (CRL) 15,061 341.7 - 2.1% 70% above
Lantheus Holdings (LNTH) 6,677 25.4 - - 513% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 874716.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: IDXX annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in IDXX

Does IDEXX Laboratories have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: IDXX

This example shows how we apply the Trendshare checklist to IDXX: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 676.21
    • Market cap: $53B
    • EPS: 14.84
  2. Step 2 — Valuation checks

    • P/E: 45.567
    • FCF yield: 0.4%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.